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Proton therapy was
associated with a low rate of
grade 2 or higher gastroin-
testinal toxicity in patients
undergoing both investiga-
tional and outcome tracking
protocols, predominantly
transient rectal bleeding,
which was highly correlated
with aspirin, anticoagulation,
and rectal dose-volume
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http://dx.doi.org/10.1016/j.ijrobp.2014.08.353Purpose: Study goals were to characterize gastrointestinal effects of proton therapy
(PT) in a large cohort of patients treated for prostate cancer, identify factors associated
with rectal bleeding (RB), and compare RB between patients receiving investigational
protocols versus those in outcome-tracking protocols.
Methods and Materials: A total of 1285 consecutive patients were treated with PT
between August 2006 and May 2010. Potential pre-existing clinical and treatment-
related risk factors for rectal toxicity were recorded. Common Terminology Criteria
for Adverse Events version 3.0 was used to score toxicity.
Results: Transient RB was the predominant grade 2 or higher (GR2þ) toxicity after
PT, accounting for 95% of gastrointestinal events. GR1 RB occurred in 217 patients
(16.9%), GR2 RB in 187 patients (14.5%), and GR3 in 11 (0.9%) patients. There were
no GR4 or GR5 events. Univariate analyses showed correlations between GR2þ RB
and anticoagulation therapy (PZ.008) and rectal and rectal wall dose-volume histo-
gram (DVH) parameters (P<.001). On multivariate analysis, anticoagulation therapy
(PZ.0034), relative volume of rectum receiving 75 Gy (V75; PZ.0102), and relative
rectal wall V75 (PZ.0017) were significant predictors for G2þ RB. Patients treated
with investigational protocols had toxicity rates similar to those receiving outcome-
tracking protocols.D, University of Florida
t. Jacksonville, FL 32206.
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Volume 91  Number 1  2015 Rectal toxicity after proton therapy 173Conclusions: PTwas associated with a low rate of GR2þ gastrointestinal toxicity, pre-
dominantly transient RB, which was highly correlated with anticoagulation and rectal
DVH parameters. Techniques that limit rectal exposure should be used when possible.
 2015 Elsevier Inc.Introduction
External beam radiation treatment (EBRT) is commonly
used to treat localized prostate cancer. The most common
source for EBRT has been x-rays. With sophisticated x-ray
delivery techniques, such as intensity modulated radiation
therapy (IMRT), which permit delivery of high doses of
radiation to the prostate and low to moderate doses to
normal tissues, patients have experienced a reduction in
radiation toxicity (1). This reduction in toxicity has
permitted dose escalation, resulting in increased efficacy (2,
3). The use of protons in lieu of x-rays as the source for
EBRT may offer further reduction in toxicity and
improvement in efficacy by reducing the incidental radia-
tion dose to normal tissues. Reports from Loma Linda
University Medical Center (LLUMC; Loma Linda, CA) in
which proton therapy (PT) alone has been used to treat
prostate cancer (4, 5) and studies of PT in combination with
x-ray therapy (6) have shown grade 3 (GR3) rectal toxicity
rates of <1%.
Recent studies using the Medicare database, however,
have implied higher rates of rectal toxicity (7-9) in patients
receiving PT than previously reported and, in some
instances, higher than in patients receiving IMRT. These
studies have been criticized for dependence on correlative
data (eg Medicare claims codes) rather than physician-
assessed toxicity or patient-reported outcomes (10).
Early toxicity and 5-year results from 3 prospective PT
protocols conducted at our institution showed low rates
of gastrointestinal (GI) and genitourinary (GU) toxicity
(11-13), mirroring the LLUMC reports. The purposes of the
present study was to confirm our early findings with a
larger population of patients and to identify clinical and
treatment factors associated with rectal toxicity.Methods and Materials
The medical records of 1538 consecutive patients with
localized prostate cancer treated with PT at our institution
between August 2006 and May 2010 were reviewed under
institutional review board approval. Patients were excluded
from analysis if they had hypofractionation protocols
(nZ141), PT for salvage therapy (nZ14), or pelvic IMRT
(nZ60) or had non-hemorrhoidal rectal bleeding (RB;
nZ1) or colostomy (nZ2) prior to PT. Thirty-five addi-
tional patients were excluded for inadequate data contri-
bution, including 19 who refused follow-up, 8 who refused
to complete questionnaires, 3 who died of nonetreatment-
related causes, and 5 who discontinued treatment fornon-GI toxicity. A previous report included 211 patients
enrolled in early investigational protocols (IP) (11) (the
primary purpose of which was to establish benchmarked
outcomes for patients receiving PT for localized prostate
cancer), including 2 excluded from this analysis because of
death from nonetreatment-related causes during or within a
month of PT. The analysis thus consists of 1285 patients
with baseline characteristics shown in Table 1, of whom
209 were undergoing IP. An additional 1076 patients were
enrolled in an outcome-tracking protocol (OTP) in which
data were collected prospectively at the same regular
follow-up intervals as IP patients, with additional data
collected between follow-up visits if toxicity, disease
recurrence, or other serious adverse events developed. The
primary difference between the IP and OTP was in exclu-
sion criteria; the IP did not enroll patients whose medical
history included a factor that could confound interpretation
of outcomes, such as a previous malignancy, whereas all
treated patients were eligible for the OTP.
All patients had outside pathology reviewed at our
institution to ensure consistency of diagnosis and Gleason
grading. All patients had pretreatment serum prostate-
specific antigen (PSA) and complete blood count and
blood chemistry tests, pelvic computed tomography (CT),
and magnetic resonance imaging (MRI), unless contra-
indicated. Patients with intermediate- and high-risk disease
had bone scans. After May 2009, screening colonoscopies
were required before PT to lessen concerns about potential
malignant sources of post-treatment RB.
Treatment simulation and planning
The treatment simulation and planning processes have been
described in detail previously (11). All patients underwent
intraprostatic fiducial marker placement followed by CT
simulation in a vacuum-locked body mold with 100 to
200 cm3 saline instilled in the rectum. After May 2008, all
patients had rectal balloons inflated with 80 to 100 cm3 of
saline for prostate stabilization. A planning MRI was also
obtained with a Panorama model 0.23-T open MRI system
(Philips, Amsterdam, the Netherlands) in patients able to
tolerate MRI scanning, which was then fused with the CT
for target and critical organ delineation. The rectum was
manually contoured by dosimetrists, from the ischial
tuberosity inferiorly to the sigmoid flexure superiorly. The
rectal wall was constructed as 3-mm thick wall structures
within the volume of the rectum.
The clinical target volume (CTV) included only the
prostate in low-risk patients or the prostate and proximal
2 cm of seminal vesicles in intermediate- and high-risk
Table 1 Baseline characteristics for 1285 patients undergoing proton therapy for prostate cancer
Characteristics
No. of patients
All (nZ1285) OTP (nZ1076; 84%) IP (nZ209; 16%)
Median age, y (range) 66 (41 to >89) 66 (42 to >89) 68 (41 to 88)
Ethnicity
White 1173 (91%) 984 (91%) 189 (90%)
Black 78 (6%) 65 (6%) 13 (6%)
Other 34 (3%) 27 (3%) 7 (3%)
Body mass index
<30 943 (73%) 779 (72%) 164 (78%)
30 342 (27%) 297 (28%) 45 (22%)
Diabetes
No 1117 (87%) 939 (87%) 178 (85%)
Yes 168 (13%) 137 (13%) 31 (15%)
History of hemorrhoids
No 819 (64%) 671 (63%) 148 (71%)
Yes 462 (36%) 401 (37%) 61 (29%)
Unknown 4 (<1%) 4 (<1%) 0 (0%)
Daily aspirin
No 806 (63%) 690 (64%) 116 (56%)
Yes 479 (37%) 386 (36%) 93 (44%)
Anticoagulation*
No 1167 (91%) 984 (91%) 183 (88%)
Yes 118 (9%) 92 (9%) 26 (12%)
Prostate size
<60 cc 1094 (85%) 918 (85%) 176 (85%)
60 cc 187 (15%) 156 (15%) 31 (15%)
Unknown 4 (<1%) 2 (<1%) 2 (<1%)
Alpha-blocker use
No 727 (57%) 643 (60%) 84 (40%)
Yes 558 (43%) 433 (40%) 125 (60%)
AUA score
<15 1032 (82%) 864 (82%) 168 (80%)
15 228 (18%) 187 (18%) 41 (20%)
Unknown 25 (<0%) 25 (<0%) 0 (0%)
Risk group
Low 540 (42%) 451 (42%) 89 (43%)
Intermediate 547 (43%) 466 (43%) 81 (39%)
High 198 (16%) 159 (15%) 39 (19%)
Gleason score
5 6 (1%) 6 (1%) 0 (0%)
6 629 (49%) 524 (49%) 105 (50%)
7 483 (38%) 414 (38%) 69 (33%)
8þ 167 (13%) 132 (12%) 35 (17%)
Tumor stage
T1c 939 (73%) 804 (75%) 135 (65%)
T2 338 (26%) 269 (25%) 69 (33%)
T3/4 8 (1%) 3 (<1%) 5 (2%)
PSA ng/ml
<4.0 204 (16%) 181 (17%) 23 (11%)
4.0-9.9 873 (68%) 730 (68%) 143 (68%)
10.0-19.9 170 (13%) 135 (13%) 35 (17%)
20.0 38 (3%) 30 (3%) 8 (4%)
Treatment start date
Before May 2008 434 (34%) 225 (21%) 209 (100%)
May 2008 to May 2010 851 (66%) 851 (79%) 0 (0%)
Androgen deprivation therapy
No 1060 (82%) 908 (84%) 152 (73%)
Yes 225 (18%) 168 (16%) 57 (27%)
(continued on next page)
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Table 1 (continued )
Characteristics
No. of patients
All (nZ1285) OTP (nZ1076; 84%) IP (nZ209; 16%)
Radiation dose, CGE
<78 15 (1%) 14 (1%) 1 (0.5%)
78 1058 (82%) 920 (86%) 138 (66%)
>78 212 (17%) 142 (13%) 70 (33.5%)
Rectal wall V75
<9.2% 499 (38.9%) 458 (42.6%) 41 (19.6%)
9.2% 785 (61.1%) 617 (57.4%) 168 (80.4%)
Relative rectum V75
<9.4% 1058 (82.4%) 914 (85.0%) 144 (68.9%)
9.4% 226 (17.6%) 161 (15.0%) 65 (31.1%)
Abbreviations: AUA Z asymptomatic urinary abnormalities; IP Z investigational protocol; OTP Z outcomes tracking protocol; PSA Z prostate-
specific antigen.
* Specific prescription anticoagulants, other than aspirin, included clopidogrel (Plavix) and warfarin (Coumadin).
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were 8 mm and 6 mm beyond the CTV in the superior-
inferior and axial planes, respectively; in May 2008, these
expansions were reduced to 6 mm and 4 mm, respectively,
after review of daily image guidance data with balloon
stabilization. Patients were treated with lateral or lateral-
oblique beams, typically with only 1 field each day. Pros-
tate position was verified before delivery of each treatment
field, using x-ray guidance and fiducial markers.Target and normal tissue dosimetric specifications
In total, 98.8% of patients (99.5% of IP and 98.7% of OTP
patients) received a treatment dose in the range of 78 to 82Gy
(relative biological effectiveness [RBE]). The median dose
for all patients was 78 Gy (RBE) (range, 72-82.3 Gy [RBE]),
78Gy (RBE) for IP patients (range, 76.0-82.0 Gy [RBE]) and
78 Gy (RBE) for OTP patients (range, 72-82.3 Gy [RBE]).
Dosimetric specifications required that 95% of the target
receive 100% of the prescribed dose and 100% of the target
receive at least 95% of the prescribed dose. Dose constraints
to organs at risk (OAR) included a rectal wall volume
receiving at least 70 Gy (RBE) (V70) of <30% and V50 of
<50% and a bladder wall V82 of<7 cm3, a V80 of<8 cm3,
and a V30 of <35 cm3. Patients in the low-risk IP received
78 Gy (RBE) to the prostate, whereas intermediate-risk IP
permitted dose escalation to 78 to 82 Gy (RBE) to the
prostate and proximal seminal vesicles when OAR dose
constraints were met. High-risk IP patients received 78 Gy
(RBE) with concomitant weekly docetaxel, followed by
6 months of androgen deprivation (ADT). OTP patients
received predominantly 78 Gy (RBE) when OAR dose
constraints were met; high-risk patients were also offered
ADT. ADT was administered by referring physicians, and
dose and duration of treatment were not recorded. Our
recommendation was 6 months of ADT in patients with only
1 high-risk characteristic but up to 24 months in those with
multiple high-risk features.Outcome measurement and follow-up
Toxicity grading was based on Common Terminology
Criteria for Adverse Events, version 3.0 (CTCAE) (14) and
occurred weekly during treatment and at 6-month intervals
afterward. Specific GI symptoms evaluated included diar-
rhea, proctitis, abdominal cramping, fecal incontinence,
and RB. Pre-existing clinical conditions that might
contribute to toxicity, such as hemorrhoids, diabetes, and
use of aspirin and anticoagulants, were recorded. Acute
toxicity was defined as occurring either during PT or up to
90 days after completion of PT with late toxicity at any
point after this. GR2 RB occurred acutely in only 2 of 1285
patients, both of whom had pre-existing hemorrhoids, so
the focus of this report is on late rectal toxicity. Antico-
agulant use was recorded prospectively at the time of initial
consultation for radiation, although details regarding dose
and duration of anticoagulant therapy were not recorded. In
a few cases of prolonged rectal bleeding, anticoagulation
was discontinued with approval of primary care physicians.
For the purposes of further characterizing RB-related
toxicity, CTCAE version 3.0-related GR2 RB was sub-
divided by intervention into medical (GR2A) such as pre-
scribed rectal suppositories, procedural (GR2B), which
included minor cautery and topical formalin application,
and hyperbaric oxygen administration (GR2C). The mini-
mum potential follow-up was 2 years; the median actual
follow-up for all patients was 3.5 years, with 91% of
patients with at least 2-year follow-up and 76% with 3-year
follow-up, 37% with 4-year follow-up, and 14% with at
least 5 years of follow-up.Statistical analysis
Statistical computations were performed with SAS (SAS
Institute, Cary, NC) and JMP software. The Kaplan-Meier
product limit method and log-rank test were used to assess
the impact of selected prognostic factors on GR2 or higher
Fig. 1. Actuarial rate of rectal bleeding as a function of
modified CTCAE v.3.0 severity scores. Grade 2þ includes
all medical and procedural interventions for rectal bleeding,
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were performed with proportional hazards regression.
Backward selection assured the most parsimonious multi-
variate final model. Significant P values, hazard ratios, and
confidence intervals for any significant variables reflect the
final model, whereas non-significant P values, hazard ra-
tios, and confidence intervals reflect their value in the full
model. For both univariate and multivariate analyses, a post
hoc Bonferroni adjustment was applied to the resulting
P values; a value was increased proportionately to the
number of prognostic factors considered. Prior to these
analyses, the most optimal break points for each of a series
of dosimetric parameters were determined with recursive
partitioning. Each dosimetric parameter was reformatted as
a binary variable based on the optimal break point before
univariate and multivariate analyses. Two-sided P values
of  .05 were considered statistically significant.whereas GR2Bþ includes only procedures such as cauter-
ization and formalin and hyperbaric treatments, excluding
those patients treated with suppositories. CTCAE
v.3.0 Z Common Terminology Criteria for Adverse
Events, v3.0; GR2Bþ Z grade 2B or higher (toxicity).Results
Rates of rectal bleeding
The majority of GR2þ GI toxicity (95%) was related to
RB. Most rectal bleeding was minimal, noted only with
bowel movements, evident only as trace blood in stools or
on toilet paper, and transient, beginning discretely some
months after radiation and gradually completely resolving
with or without intervention. Of the 1285 patients in this
study, 415 (32.1%) admitted to post-treatment RB at some
point during follow-up. The 217 patients (16.9%) with a
maximum of GR1 RB included 195 patients who received
no medications (15.2%) and 22 (1.7%) who took a short
course of over-the-counter vitamin A, which has been
shown to alleviate radiation proctitis (15, 16). The 187
patients with a maximum toxicity of GR2 (14.5%) were
classified by intervention into GR2A medical, GR2B pro-
cedural, and GR2C hyperbaric oxygen. The 126 GR2A
patients (9.8%) were given only rectal suppositories, 58
GR2B patients (4.5%) were treated with minor cautery or
topical formalin application, and 3 GR2C patients (0.2%)
received hyperbaric oxygen therapy. Eleven patients (0.9%)
had a maximum of GR3 toxicity, including 8 (0.6%) who
required transfusion, 2 who had formalin infusion (0.2%),
and 1 (0.1%) who required a temporary, elective colostomy
owing to development of hemorrhagic rectal ulceration
following unauthorized biopsy of a telangiectatic rectal
area performed by an outside gastroenterologist, which was
subsequently successfully reversed. There were no GR4 or
GR5 events. Post-treatment RB rates are shown in Figure 1.
The overall GR2þ RB rate was 15.4% (198 patients). Ten
patients had late GR2þ GI toxicities other than RB,
including 7 patients with proctitis, 2 patients with transient
episodes of rectal incontinence, and 1 patient with diarrhea.
The onset of RB in most cases (98.1%) occurred within
3 years of completing treatment at a median of 12 months.
RB began before 6 months in 32 patients (7.7%), between 6and 12 months in 173 patients (41.7%), between 12
and 18 months in 112 patients (27.0%), between 18 and
24 months in 46 patients (11.1%), and between 24 and
36 months in 44 patients (10.6%).Univariate and multivariate analyses of factors
associated with rectal bleeding
Table 2 shows the results of univariate and multivariate
analyses of factors potentially associated with GR2þ RB.
On univariate analysis, anticoagulant use (PZ.008) was
significantly associated with GR2þ RB. Multiple rectum
(RE) and rectal wall (RW) dose-volume histogram (DVH)
parameters were also associated with GR2þ RB on uni-
variate analysis, including both relative and absolute dose
levels to both the RE and to the RW ranging from 30 Gy
(RBE) to 75 Gy (RBE). Figure 2 shows the relationship
between RB and increasing RE and RW DVH parameters
with a table showing the most sensitive breakpoints for
each DVH parameter. For simplification, only 4 DVH pa-
rameters were selected for evaluation in a multivariate
analysis: percentage of RE (%RE) V30, %RE V75, %RW
V30, and %RW V75. On multivariate analysis (Table 2),
only the use of anticoagulants, %RE V75, and %RW V75
remained significant predictors for GR 2 þ RB.
Tables 3 and 4 show the rate of GR2 overall and
GR2B þ RB, respectively, as a function of %RE V75, %
RW V75, aspirin usage, and anticoagulation therapy.
Patients not taking aspirin had rates of GR2B þ RB of
4.3% versus 7.7% in those taking aspirin. Patients not
taking anticoagulation regimens had rates of GR2B þ RB
of 4.5% versus 16.9% (P<.0001) in those receiving anti-
coagulation. The risk of GR2B þ RB was highest (23%) in
Table 2 Factors associated with grade 2 or higher rectal bleeding
Factor
3-Year
rate
Control group for
hazard ratios
Univariate proportional
hazards regression
Multivariate proportional
hazards regression
Yes No P value
Hazard
ratio
95% confidence
interval P value
Hazard
ratio
95% confidence
interval
Aspirin 19.4 14.3 Yes aspirin .5820 0.7 0.5-1.1 .8041 0.8 0.5-1.2
Pretreatment diabetes 16.3 16.2 Yes diabetes .9999 1 0.5-1.8 .9999 1.1 0.6-2.0
Anticoagulation 29.7 14.9 Yes anticoagulation .0080 0.5 0.3-0.8 .0034 0.5 0.3-0.9
Pretreatment hemorrhoids 16.3 16.1 Yes hemorrhoids .9999 1 0.6-1.5 .9999 0.8 0.5-1.3
Prostate volume <60 cm3 16.5 14.5 60 cm3 .9999 1.2 0.6-2.3 .9999 1.6 0.8-3.1
Alpha-blocker (pre- or
post-treatment)
18.1 14.8 No alpha blocker .9999 1.2 0.8-1.9 .9999 1.2 0.7-1.8
International prostate
symptom score <15
16 17.7 15 .9999 0.9 0.5-1.5 .9999 0.8 0.5-1.4
Age, y < 60 14.3 16.7 60 .9999 0.9 0.5-1.5 .9999 0.9 0.5-1.7
Body mass index <30 16.1 16.5 30 .9999 1 0.6-1.6 - - -
Risk level* Low risk .9999 1.1 0.6-2.0 .9999 0.8 0.4-1.8
Androgen deprivation
therapy
17.2 16.1 No androgen
deprivation therapy
.9999 1.1 0.6-1.9 .9999 1 0.5-2.1
Dose 78 Gy(RBE) 15.1 22.2 >78 Gy .3380 0.7 0.4-1.1 .9999 0.9 0.4-1.8
Ethnicity (white) 16.4 14.8 White .9999 0.9 0.4-2.0 .9999 0.9 0.4-2.1
Treatment before May 2008 19.7 14.4 May 2008 .5500 1.4 0.9-2.1 .9999 0.8 0.5-1.4
Treatment before May 2009 17.1 14.3 May 2009 .9999 1.2 0.7-1.9 - - -
Treated on investigational
protocoly
21 18.4 Yes protocol .9999 0.8 0.4-1.6 - - -
Relative rectum
V30 (%) < 26.4%z
13.3 24.3  26.4% .0006 0.5 0.3-0.8 .9999 0.9 0.4-2.3
Relative rectum
V75 (%) < 9.4%z
13.5 28.9  9.4% <.0001 0.4 0.3-0.7 .0102 0.6 0.3-0.9
Relative rectal wall
V30 (%) < 27.7%z
13 23.5  27.8% .0008 0.6 0.4-0.8 .9999 1 0.4-2.2
Relative rectal wall
V75 (%) < 9.2%z
8.3 21.1  9.2% <.0001 0.4 0.2-0.7 .0017 0.5 0.3-0.9
* Three-way comparison between low, intermediate, and high risks. Hazard ratios and confidence intervals in the table indicate the widest ranges.
y Analysis of rectal bleeding risks between patients undergoing interventional protocols (IPs) and the outcome tracking protocol was restricted to
patients treated before 2008, when the IPs were ongoing, to avoid issues of differential follow-up between the groups.
z All dose-volume histogram absolute and relative values for the rectum and rectal wall were highly statistically correlated with the risk of rectal
bleeding; for purposes of analysis, only data for lowest and highest values tested are shown.
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V75  9.2%. Figures 3 and 4 show the actuarial rates of
GR2 and GR2B þ respectively with respect to anticoagu-
lant status and %RW V75. Three-year freedom from GR2
RB for patients with RW V75 of <9.2% not receiving
anticoagulation therapy was 92.4% versus 62.7% for
patients with RW V75 > 9.2% who were receiving anti-
coagulation. For GR2B þ RB, the corresponding rates were
97.1% for patients not receiving anticoagulation with RW
V75 < 9.2% and 77.3% for those with RW V75 > 9.2%
who were receiving anticoagulation (P<.0001).Discussion
This study presents the largest prospective assessment of
rectal toxicity to date in cases if localized prostate cancer
treated solely with PT. Our results demonstrate that the
most physician-reported toxicity in prostate cancer treatedwith PT is transient RB. Our data show low rates of GR2
and GR3 RB (14.5% and 0.9%, respectively) compared
with some previously reported 3-dimensional (3D)
conformal RT (3DCRT) (17-19) and IMRT (20, 21) dose-
escalated studies. Specifically for IMRT, DeMeerleer et al
(20) and Vora et al (21) reported late GR2 GI toxicity rates
(both studies used modified versions of the Radiation
Therapy Oncology Group [RTOG] scale) of 18% and 24%,
respectively, using IMRT up to 76 Gy, whereas for 3DCRT,
Pollack et al (17) reported a GR2þ late GI toxicity rate of
26% in patients receiving 78 Gy in 39 fractions.
Some series (2, 22, 23) have reported lower rectal
toxicity with dose-escalated IMRT above 78 Gy. For
example, Spratt et al (2) reported a GR2þ GI toxicity rate
(per CTCAE version 4.0) of 4% after doses of up to
86.4 Gy with IMRT. However, most of these appear to be
predominantly retrospective studies, in contrast to the
prospective study we report herein. Individual categorized
toxicities such as rectal suppository use were not reported
Fig. 2. Relationship between risk of GR2þ rectal
bleeding and increasing percentage of rectal or rectal wall
volumes receiving dose levels of 30, 50, and 75 CGE.
Break points that best dichotomized the risk of GR2þ
rectal bleeding for dose levels of 30, 50, and 75 CGE were
9.4%, 18.9%, and 26.4%, respectively, for the rectum and
9.2, 21.0, and 27.8%, respectively, for the rectal wall.
GR2Bþ Z grade 2B or higher (toxicity).
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these individual toxicities were prospectively recorded
and reported. A typical medical record might not consis-
tently capture over-the-counter medical interventions or
symptoms for which no intervention was given, so it is
possible that studies not designed prospectively to capture
such events could underestimate the prevalence of such
symptoms and interventions.
Data in our study compare favorably to those of previ-
ously reported PT series (4, 6, 24, 25). LLUMC reported
3-year GR2þ GI toxicity rates of 21% (4), using the RTOG
late effects scale (26). Zietman et al (6) reported GR 2 þ GI
toxicity of 17% in patients treated with 79.2 Gy with
combined photons and protons, whereas Nihei et al (27)
reported rates of GR2 rectal toxicity of 2% with PT,
using a different scoring system, CTCAE version 2.0. (28).
Again, just as with the dose-escalated IMRT series, specific
interventions that were counted in the current study as GR2Table 3 Rate of grade 2 or higher rectal bleeding as a function of
Factor
No. of p
Aspirin therapy
No Yes
Grade 2þ/total 109/806 (13.5%) 89/479 (18.
Relative rectum V75 (%)
<9.4 73/668 (10.9%) 63/390 (16.
9.4 36/137 (26.3%) 26/89 (29.
Relative rectal wall V75 (%)
<9.2 21/314 (6.7%) 20/185 (10.
9.2 88/491 (17.9%) 69/294 (23.toxicity (eg cortisone suppositories) are not specifically
reported in previously published PT series, making direct
comparisons difficult. In addition, scoring criteria vary
among toxicity scoring systems, further complicating
comparisons across studies regardless of treatment modal-
ity. Because most toxicity scoring systems are dependent on
interventions and because preferences among physicians
for interventions differ, standardized health-related quality-
of-life questionnaires may be a useful tool for toxicity
comparisons among different cohorts; Expanded Prostate
Cancer Index Composite questionnaire data from this
population is currently under analysis.
Our study provides a description of the most significant
intervention for patient toxicity, which may offer patients
more accurate expectations regarding toxicity risks. Most
patients required minimal or no intervention. In contrast
with dose-escalated IMRT experiences (2), which suggest a
steady increase in bowel toxicity over time, in the LLUMC
experience of 1255 patients, Slater et al (4) reported that all
severe GI toxicity from PT manifested in the first 2.5 years
after treatment. Similarly, Nihei et al (27) reported that RB,
which was the most common late rectal toxicity, occurred
within 2 years of treatment. In our study, 98.3% of cases of
RB started within 3 years of PT and 87.7% within 2 years.
Because 91% and 76% of patients had a minimum actual
2- or 3-year follow-up, it is likely that most of the
physician-reported rectal toxicity occurring within this time
frame was captured in our analysis. Clearly, longer follow-
up is needed to confirm this possible difference in the
pattern of late bowel toxicity between IMRT and PT; it is
possible that other patterns of late GI toxicity will emerge
with longer follow-up after PT.
We found toxicity outcomes in patients treated with
specific IPs that were the same as those treated with OTPs.
Because surveillance strategies for the IPs and OTPs were
identical, this finding confirms the low toxicity rates pre-
viously reported in patients in IPs (11), and the generaliz-
ability of these findings to other patients treated with PT in
a similar fashion with similar doses.
Previous reports from the Surveillance, Epidemiology,
and End Results database (7-9) and Medicare claims data
have suggested that PT may be associated with greater GI
toxicity than IMRT. Criticism of these studies includes thepredictive factors
atients/total no. of patients (%)
Anticoagulation therapy
No Yes
6%) 166/1167 (14.2%) 32/118 (27.1%)
2%) 112/960 (11.7%) 24/98 (24.5%)
2%) 54/206 (26.2%) 8/20 (40.0%)
8%) 35/454 (7.7%) 6/45 (13.3%)
5%) 131/712 (18.4%) 26/73 (35.6%)
Table 4 Rate of grade 2B or higher rectal bleeding as a function of predictive factors
Factor
No. of patients/total no. of patients (%)
Aspirin therapy Anticoagulation therapy
No Yes No Yes
Grade 2Bþ/Total 35/806 (4.3%) 37/479 (7.7%) 52/1167 (4.5%) 20/118 (16.9%)
Relative rectum V75 (%)
<9.4 25/668 (3.7%) 29/390 (7.4%) 38/960 (4.0%) 16/98 (16.3%)
9.4 10/137 (7.3%) 8/89 (9.0%) 14/206 (6.8%) 4/20 (20.0%)
Relative rectal wall V75 (%)
<9.2 9/314 (2.9%) 8/185 (4.3%) 14/454 (3.1%) 3/45 (6.7%)
9.2 26/491 (5.3%) 29/294 (9.9%) 38/712 (5.3%) 17/73 (23.3%)
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actual clinical outcomes, the comparison between large,
population-based data for IMRT and 3DCRT and small-
population data from a single institution for PT, and the
absence of critical prognostic data, such as radiation pre-
scription dose, fractionation, and DVH parameters (signif-
icantly associated with RB rates in the present study). The
actual low rate of significant GI toxicity documented in our
study underscores the possibility that studies relying on
such surrogate data may lead to erroneous conclusions.
Two prognostic factors were found to be significantly
associated with RB: the volume of RE or RW exposed to
various radiation dose levels and the use of anticoagulants.
These RE or RW DVH parameters were correlated with
other factors such as prescribed dose, prostate size, and
treatment and prostate stabilization techniques. Higher ra-
diation doses for prostate cancer have been associated with
higher rates of GI toxicity, for example, Zietman et al (6),
reporting long-term outcomes of the PROG 9509 study
randomizing patients between 70.2 CGE and 79.2CGE
(50.4 Gy by photons followed by a proton boost), demon-
strated an increased risk of GR2þ GI toxicity with higherFig. 3. Actuarial rate of freedom from GR2þ rectal
bleeding with respect to anticoagulant use and rectal wall
%V75. %V75Z percentage of the target volume receiving
75 Gy. GR2Bþ Z grade 2B or higher (toxicity).doses of PT (13% vs 24%, respectively). The distinction
between rectal DVH factors and prescribed dose to the
prostate target volume (29) as the primary risk factor for
rectal injury is critical as technical variations now and in
the future may achieve rectal tissue dose constraints while
permitting dose escalation or hypofractionation strategies
that achieve better outcomes in terms of disease control or
patient convenience. In the current study, the use of a rectal
balloon permitted a reduction in PTV expansion, which we
believe accounts for the reduction in GR2þ RB rates over
time. Techniques currently under investigation that increase
the distance between the prostate target volume and the RW
by inserting slow absorption gels (30) may have a signifi-
cant impact on rectal toxicity in the future. For now, the
current study clarifies the relationship between rectal injury
from PT and dose-volume relationships for rectal tissue that
may be helpful in establishing future treatment planning
guidelines for protection of OARs.
The use of anticoagulant agents was also associated with
an increased risk of GR2þ RB. This risk with anticoagu-
lants was double the risk with aspirin. Patients taking an-
ticoagulants also required procedural interventions such asFig. 4. Actuarial rate of freedom from GR2B þ rectal
bleeding with respect to anticoagulant use and rectal wall
% V75. % V75 Z percentage of the target volume
receiving 75 Gy. GR2Bþ Z grade 2B or higher (toxicity).
Colaco et al. International Journal of Radiation Oncology  Biology  Physics180topical formalin and minor cautery 3.7 times more
frequently than patients not using anticoagulants. Some
investigational studies exclude patients receiving anti-
coagulation therapy (25), making toxicity results less
generalizable to the overall population. Takeda et al (31)
also reported increased GR2þ GI toxicity in patients tak-
ing anticoagulants treated with 3DCRT or IMRT. In 718
men treated with EBRT to doses 75 Gy, Hamstra et al
(32) reported GR2þ GI toxicity rates of 26.4% in patients
taking anticoagulants compared to 11.3% in patients not
taking anticoagulants (PZ.004).
More stringent dose constraints to the RE and RW may
be warranted in patients taking anticoagulants. Patients may
benefit from education by their health-care team regarding
RB expectations and risk minimization strategies such as
maintenance of regular bowel function and avoidance of
potentially harmful interventions. Current colonoscopies
before PT can reduce the concern for RB related to other
causes and the need for colonoscopic examinations during
the risk period for RB. Prospective patient education on the
pathophysiology of RB, potential benefits of avoiding
dehydration or constipation, early notification of the health-
care team if RB is observed, and the value of hemoglobin
and hematocrit monitoring may allay patient concerns and
pre-empt unnecessary potentially harmful interventions. In
our experience, most cases of RB resolve without inter-
vention. When RB occurs, we encourage good bowel
function with hydration and stool softeners and rely on
observation unless bleeding is prolonged, occurs outside
normal bowel movements, or there is evidence of hemo-
globin drop. When intervention is deemed necessary, our
preferred order of interventions is: (1) over-the-counter
vitamin therapy; (2) rectal suppositories, if necessary; and
(3) topical formalin applications, only if deemed necessary
by an experienced gastroenterologist and colorectal sur-
geon. Occasionally, hyperbaric oxygen therapy or multiple
topical formalin applications are recommended. Rarely,
formalin rectal infusion has been recommended. Patients
are strongly encouraged to avoid invasive procedures such
as cautery and argon plasma laser coagulation as some
patients have anecdotally had clinical deterioration with
these interventions. Rectal biopsy should be discouraged
unless there is evidence suggesting prostate cancer pro-
gression (eg PSA rise or increasing mass on MRI or digital
rectal examination) or a rectal tumor.Conclusions
In our study, PT was associated with low rates of GR2þ GI
toxicity, the most common event being transient RB. RB is
typically minimal and resolves without intervention. Ra-
diation exposure to rectal tissue and anticoagulant use are
correlated with the risk of GR2þ RB following PT.
Although rates of GR2þ RB are low, even among anti-
coagulated patients, patients taking such medications may
benefit from more intensive monitoring after PT.Techniques that limit rectal exposure should be used when
possible. In patients undergoing anticoagulation therapy,
stricter dose constraints for rectal tissue may be warranted.References
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